• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Biotronik launches China arm in Orsiro stent trial

Biotronik launches China arm in Orsiro stent trial

August 31, 2015 By Fink Densford

Biotronik launches China arm in Orsiro stent trialBiotronik said today it enrolled the 1st patient in its new Chinese Bioflow-VI study of its Orsiro drug-eluting stent for treating patients with coronary artery disease.

The prospective, multi-center trial is slated to enroll 440 patients at 15 sites in China to support Chinese market approval of the Orsiro drug-eluting stent.

“Based on the wealth of clinical evidence demonstrating Orsiro’s safety and efficacy, I am very excited to begin enrollment in the Bioflow-VI study. This trial represents a key step in the process of bringing this remarkable product to Chinese patients. Once approved for use here, I’m convinced Orsiro will benefit Chinese patients and physicians as it does in Europe,” coordinating clinical investigator Dr. Yuejin Yang said in a press release.

The primary endpoint for the study is in-stent late lumen loss at 9 months and the primary safety endpoint is the rate of major adverse cardiac events at 1 year, according to the company.

“Our mission is to improve and save patients’ lives all over the world with innovative devices like the Orsiro hybrid DES, which has proven itself time and again both in clinical studies and in routine clinical practice. The start of Bioflow-VI is an important milestone in our quest to bring Orsiro, one of our most successful products globally and a cornerstone of the Biotronik Masterpieces portfolio, to China,” Biotronic Asia Pacific veep Gunnar Wochnowski said in prepared remarks.

Earlier this month, Biotronik announced 2 new studies that are slated to examine the company’s CRT-D device and BioMonitor implanted cardiac monitor.

A 277-patient BioContinue clinical trial will examine the risk of ventricular arrhythmias after CRT-D replacement, enrolling patients over 2 years at 40 centers across 8 countries, the company said.

Another trial, the BioGuard MI1 study, will examine the effectiveness of Biotronik’s BioMonitor at reducing the likelihood of major adverse cardiovascular events in patients with relatively preserved ejection fraction who have experienced myocardial infarction.

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Drug-Eluting Stents, Implants, Stents Tagged With: Biotronik

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy